T. Rowe Price Associates
XENE icon

T. Rowe Price Associates’s Xenon Pharmaceuticals XENE Stock Holding History

T. Rowe Price Associates’s Portfolio XENE Stock Details XENE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$196M Buy
3,248,219
+1,918,628
+144% +$107M 0.02% 516
2026
Q1 		$77.3M Buy
1,329,591
+467,291
+54% +$21.5M 0.01% 664
2025
Q4 		$38.6M Buy
862,300
+820,608
+1,968% +$34.5M ﹤0.01% 884
2025
Q3 		$1.68M Buy
41,692
+3,757
+10% +$132K ﹤0.01% 1812
2025
Q2 		$1.19M Buy
+37,935
New +$1.24M ﹤0.01% 1904

Other funds holding XENE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

T. Rowe Price Associates's XENE Position: Q2 2026 in Review

T. Rowe Price Associates increased its Xenon Pharmaceuticals (XENE) stake by 144% in Q2 2026, buying an estimated $107M and bringing the position to 3,248,219 shares worth $196M. The position accounts for 0.02% of the portfolio, ranked #516.

T. Rowe Price Associates first reported a position in XENE in Q2 2025 and has held it in 5 quarters since. 315 funds tracked by Wall St. Rank hold XENE as of Q2 2026.

  • T. Rowe Price Associates held 3,248,219 shares of Xenon Pharmaceuticals worth $196M as of Q2 2026.
  • T. Rowe Price Associates bought 1,918,628 Xenon Pharmaceuticals shares in Q2 2026, an estimated $107M.
  • Xenon Pharmaceuticals made up 0.02% of T. Rowe Price Associates's portfolio in Q2 2026, its #516 holding.
  • T. Rowe Price Associates first reported a position in Xenon Pharmaceuticals in Q2 2025 and has held it in 5 quarters since.
  • 315 funds tracked by Wall St. Rank held Xenon Pharmaceuticals as of Q2 2026.

Based on T. Rowe Price Associates's 13F filing for Q2 2026, filed 14 Aug 2026.